Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series
Swiss Medical Weekly · 2024
DOI: 10.57187/s.3771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Swiss Medical Weekly, 2024. Verfasst von Cindy Pereira Portela und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Gastric Bypass, Maltose, Ferric Compounds, Phosphates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
AIMS: Bariatric surgery induces several micronutrient deficiencies that require supplementation. For iron, parenteral infusions are usually preferred over oral supplementation. Ferric carboxymaltose infusion has been associated with hypophosphataemia, mostly transient and asymptomatic. However, in some cases, ferric carboxymaltose-induced hypophosphataemia may persist for weeks to months and may induce muscle weakness, osteomalacia and bone fractures. The aim of this study was to identify possible predictors of a clinically relevant decrease in serum phosphate after ferric carboxymaltose infusion in patients with previous Roux-en-Y gastric bypass. METHODS: Patients with previous Roux-en-Y gastric bypass who received ferric carboxymaltose infusions between January 2018 and September 2019 and had recorded phosphataemia before and after ferric carboxymaltose infusion at the Lausanne University Hospital, Lausanne, Switzerland, were studied retrospectively. A multiple linear regression model was built with delta phosphataemia as the outcome to investigate the factors related to magnitude of serum phosphate lowering. RESULTS: Seventy-seven patients (70 females and 7 males) with previous Roux-en-Y gastric bypass were studied. Mean age (SD) was 43.2 (10.7) years and median BMI was 30.9 kg/m2 (IQR 27.9–36.4). Sixty-eight patients (88.3%) received an infusion of 500 mg ferric carboxymaltose and 9 patients (11.7%) received 250 mg ferric carboxymaltose. Forty-nine patients (63.6%) developed hypophosphataemia (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland.
- Service of Endocrinology, Diabetes and Metabolism, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland.
- Biostatistic Unit, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
- Service of Nephrology, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland and Department of Medical Biosciences, University of Lausanne, Lausanne, Switzerland.
- Service of Nephrology, Department of medicine, Fribourg State Hospital and University of Fribourg, Fribourg, Switzerland.
Zitieren
APA
Pereira Portela, C., Favre, L., Locatelli, I., & Bonny, O. (2024). Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series. Swiss Medical Weekly. https://doi.org/10.57187/s.3771
Vancouver
Pereira Portela C, Favre L, Locatelli I, Bonny O. Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series. Swiss Medical Weekly. 2024. doi:10.57187/s.3771
BibTeX
@article{PereiraPortela2024,
author = {Pereira Portela, Cindy and Favre, Lucie and Locatelli, Isabella and Bonny, Olivier},
title = {Intravenous ferric carboxymaltose is associated with lowering of plasma phosphate levels in patients with gastric bypass surgery: a retrospective case series},
journal = {Swiss Medical Weekly},
year = {2024},
doi = {10.57187/s.3771}
}
EUVIMED